))
#088: Immune Tolerance and MS. How the RED4MS Study Could Change MS Treatment with Dr. Andreas Lutterotti
Manage episode 451129116 series 3562061
Το περιεχόμενο παρέχεται από το Nele Handwerker. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Nele Handwerker ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.
Andreas Lutterotti explains the mode of action, the concept of the early clinical trial RED4MS, and what a success could mean for patients.
You can read through all questions and answers on my blog: https://ms-perspektive.com/88-red4ms
Multiple sclerosis is one of the absolute success stories in terms of disease-modifying therapy. Nevertheless, the search for new concepts continues and the RED4MS study is looking in a new direction. Neurologist Dr. Andreas Lutterotti and his colleagues are researching and developing a novel approach to retraining the immune system. Find out more about the RED4MS study and how this therapy aims to reduce the symptoms of MS while maintaining normal immune function, offering hope for more targeted and safer treatment.
Dr. Lutterotti provides insights into the study's objectives, patient eligibility, and what participants can expect. This early study is initially concerned with exploring the safety of the therapy. Only in the second step will the right dose be found that hits the sweet spot between efficacy and tolerability. Find out more about the possible effects of the therapy on daily life, the strict safety measures, and what might happen if the results are positive.
Table of Contents- Introduction – Who is Dr. Andreas Lutterotti?
- RED4MS: Overview of the Therapy and Potential Benefits
- RED4MS: Patient Experience and Eligibility
- RED4MS: Impact of the Therapy and Safety Monitoring
- RED4MS: Dosing and Administration
- RED4MS: Effectiveness and Expected Outcomes
- RED4MS: Long-term Implications and Availability
- Quickfire Q&A Session
- Farewell
I’m Andreas Lutterotti, originally from Austria, now living in Switzerland. I’m a neurologist with a focus on MS and a Chief Medical Officer at Cellaris AG. I’m married, have three children, and enjoy biking and traveling with my family.
Finally, what message of hope or encouragement would you like to share with the listeners?
Treatment development in MS has been very successful in a relatively short period of time. With more focus neuroprotective/-regenerative therapies and improvement of symptoms like fatigue we will hopefully improve the life of patients with MS in the future.
How and where can interested people follow your research activities?www.clinicaltrials.gov (contains a list of participating centers)
The following countries participate in the trial:
- Germany
- Czech Republic
- Switzerland
- Italy
Good luck with the clinical trial. Sounds like a promising mode of action.
See you soon and try to make the best out of your life, Nele
For more information and positive thoughts, subscribe to my newsletter for free.
Click here for an overview of all podcast episodes published so far.
85 επεισόδια
Μοίρασέ το
